Tofacitinib is the only available JAK inhibitor in the market till the date, but it is facing serious side effects like carcinogenesis,mutagenesis, impairment offertility,upper respiratory tract infections,headache,diarrhoeaandnasopharyngitis. This clearly upholds the relevance of designing new novel drugs which are devoid of these side effects and will ameliorate the JAK inhibition activity.Thetarget identification was done using Drug Bank.Theprimary and secondary protein characterisation was done using protparam and sopmarespectively. Molecular properties and the drug likeness were calculated using Biovia Discovery Studio.
V. V. and Dr. Subin Mary Zachariah, “In silico drug design of some novel compounds as an alternative for the anti IBD drugTofacitinib”, Research Journal of Chemistry and Environment, vol. 24, no. 8, pp. 11-17, 2020.